Breast Cancer Brands

Groundbreaking HER2-targeted biologic cancer therapy (trastuzumab) developed by Genentech and owned by Roche, FDA approved September 25, 1998, that transformed the treatment of HER2-positive breast cancer and now faces biosimilar competition from multiple approved alternatives.

Roche's HER2-targeted antibody-drug conjugate (ado-trastuzumab emtansine, T-DM1) developed by Genentech using ImmunoGen's DM1 cytotoxic technology, FDA approved February 22, 2013, for HER2-positive metastatic breast cancer and later for early-stage HER2-positive breast cancer following the KATHERINE trial.

Roche's HER2-targeted biologic (pertuzumab) developed by Genentech, FDA approved June 8, 2012, that targets a different HER2 domain than Herceptin and is used in combination with Herceptin and chemotherapy for HER2-positive breast cancer in both metastatic and early-stage settings.

Sanofi's taxane chemotherapy (docetaxel), FDA approved in 1996 for breast cancer and later for lung, prostate, gastric, and head and neck cancers, that generated $1.4 billion annually by 2004 before generic competition and became subject to major litigation over undisclosed risk of permanent hair loss.

Roche's oral fluoropyrimidine chemotherapy (capecitabine) developed by Genentech, FDA approved April 30, 1998, as the first oral chemotherapy for metastatic breast cancer and later for metastatic colorectal cancer, now available as generic capecitabine following patent expiration.